1989 Volume 35 Issue 6 Pages 1496-1508
Thirty female patients having xerostomia were each given one tablet of Metharmon-F, a metabolic hormone agent, per administration on a thrice daily basis for 8 consecutive weeks. We evaluated the clinical effects of Metharmon-F treatment and the following results were obtained:
1) Subjective symptoms were improved as follows: feeling of oral dryness was relieved in 30.0% of all the patients; saliva viscoid in 35.7%; intraoral pain (other than tongue) in 50.0%; dietary disorder in 37.0%; speech disorder in 50.0%; sleep disorder in 50.0%; taste abnormality in 41.7%; tongue pain in 53.3%; and strange sensation in the pharynx in 60.0%. As for objective symptoms, lingual conditions were effectively improved in 47.6% of all the patients.
2) Overall improvement was observed as follows: 3.3% of the total patients remarkably improved; 36.7% moderately improved; 50.0% slightly improved; and 10.0% remained unchanged. No deterioration was observed. In patients who had already been receiving artifi cial saliva, salivary gland hormone, or vitamins, the concomitant administration of Metharmon-F resulted in a higher improvement rate.
3) The effect of treatment is considered to appear approximately two weeks after the start of administration, Six-week consecutive administration may be required. In the Cornell Medical Index, a more favorable effect was obtained in patients with slight symptoms for items M to R.
4) Adverse effects, i. e. symptoms of slight hyperaesthesia of limbs, were observed in only one case. However, no abnormal clinical findings were noted in other patients. Therefore, it was concluded that Metharmon-F is essentially safe in clinical application.
Based on the results described above, Metharmon-F tablets were determined to be highly useful in treating xerostomia.